Friday, 16 October 2026European Markets

CHARGEURS Stock Over 9% Down So Far Today

Loading stream...

(vianews) - shares of chargeurs (cac 40: cri.pa) fell 9.99% to €12.98 at 11:51 est on wednesday, following the last session's upward trend. cac 40 is dropping 1.61% to €7,259.73, after two successive sessions in a row of losses. this seems, at the moment, an all-around down trend exchanging session today.

chargeurs's last close was €14.42, 24.03% below its 52-week high of €18.98.

about chargeurs

chargeurs sa operates as a manufacturing and services company in france, europe, the americas, asia, and internationally. the company operates through luxury and technologies segments. it provides surface solutions, such as plastic and paper films, technical adhesives, and application machinery for manufacturers of surfaces or products comprising plastics, glass, stainless steel, aluminum, pre-coated metals, and polyvinyl chloride (pvc) profiles; interlinings for the luxury and fashion industries; accessories and leather goods; and supplies wool fibers. the company is also involved in the production and sale of coats, jackets, shirts, sports clothing, and other products; and production and distribution of personal protective equipment. in addition, it offers various solutions, including strategic consulting, master planning, design, development, publishing, curation, exhibitions, marketing, merchandising, digital content, communication, etc.; and the museum studio platform that includes a portfolio of services comprising project coordination and museum installations, as well as design and the creation of immersive and technological experiences, and production of audiovisual content and the publication of art books. the company was formerly known as chargetex 1 and changed its name to chargeurs sa in 1997. chargeurs sa was founded in 1872 and is headquartered in paris, france.

earnings per share

as for profitability, chargeurs has a trailing twelve months eps of €0.92.

pe ratio

chargeurs has a trailing twelve months price to earnings ratio of 14.11. meaning, the purchaser of the share is investing €14.11 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.01%.

dividend yield

as stated by morningstar, inc., the next dividend payment is on may 2, 2023, the estimated forward annual dividend rate is 0.76 and the estimated forward annual dividend yield is 5.26%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, chargeurs's stock is considered to be oversold (<=20).

sales growth

chargeurs's sales growth for the current quarter is 7.9%.

revenue growth

year-on-year quarterly revenue growth declined by 4.5%, now sitting on 746.4m for the twelve trailing months.

more news about chargeurs (cri.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com